A large retrospective cohort shows CLDN18.2 expression does not influence outcomes of first‑line immunochemotherapy in HER2‑negative, pMMR, PD‑L1 CPS≥1 metastatic gastric/GEJ cancer.
🔗 buff.ly/rdAewUh
#GastricCancer #Immunotherapy #CLDN182 #Biomarkers
1
1
0
0
